Sign in to view content

A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)

Raj K. Maturi, MD

Video
Published 2021

Related

ASRS Presidents' Retina Young Investigators Award, Advancing Insights Into Diabetic Eye Disease, Rishi P. Singh, MD
Rishi P. Singh, MD
Annual Meeting Talks
2018
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021

Category: Pharmacology

See more